Loading...
Keywords
Last Name
Institution

Connection

Search Results to Erin M. Guest

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Guest, Erin

PropertyValue
research overview Dr. Guest's research areas of focus are in leukemia in infants, cancer genomics, and cancer predisposition syndromes. She is the study chair for the National Cancer Institute sponsored Children's Oncology Group clinical trial for infants with acute lymphoblastic leukemia (ALL) and she leads the national task force on infant ALL. Dr. Guest collaborates with researchers around the world to discover and develop new, more effective therapies for infants with leukemia.

One or more keywords matched the following items that are connected to Guest, Erin

Item TypeName
Concept Combined Modality Therapy
Concept Salvage Therapy
Concept Treatment Outcome
Concept Molecular Targeted Therapy
Academic Article Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531.
Academic Article Updates in the biology and therapy for infant acute lymphoblastic leukemia.
Grant Overcoming therapeutic resistance by repurposing a classic chemotherapeutic drug as targeted therapy to reactivate anti-cancer immunity
Academic Article Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
Academic Article Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
Academic Article Overcoming Wnt-?-catenin dependent anticancer therapy resistance in leukaemia stem cells.
Grant A multi-omics approach to overcome resistance in infant leukemia by identifying immune-therapy failure mechanisms
Academic Article Anaplastic Lymphoma Kinase Inhibitor in Treatment of Inflammatory Myofibroblastic Tumor of the Tongue in Infancy.
Academic Article Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial.
Academic Article Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Grant A CRISPR genetic screen in an induced pluripotent stem cell model to discover modifiers of therapy-related pediatric leukemia
Grant Induced pluripotent stem cell models for pediatric KMT2A-r leukemia development and discovery of targeted therapies

Search Criteria
  • Therapeutics